Brief: Insilico Medicine Receives IND Approval From FDA For ISM8969, An AI-Empowered Potential Best-In-Class NLRP3 Inhibitor
23/01/2026 13:32
Jan 23 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK: INSILICO MEDICINE RECEIVES IND APPROVAL FROM FDA FOR ISM8969, AN AI-EMPOWERED POTENTIAL BEST-IN-CLASS NLRP3 INHIBITOR INSILICO MEDICINE CAYMAN TOPCO - ENTERS CO-DEVELOPMENT AGREEMENT WITH HYGTIA THERAPEUTICS INSILICO MEDICINE - ELIGIBLE FOR UP TO $66 MILLION IN PAYMENTS UNDER DEAL Source text: ID:nPn5zcxF6a Further company coverage: 3696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7